CD8A and type 1 diabetes mellitus: For example, combination therapy with an anti-IL-21 agent to target CD8+ Teff, Th17 and Th cells and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide preserved β cell function in recent-onset T1D patients in a Phase 2 trial with a stronger safety profile than immunosuppressive, disease-modifying therapies alone (161).